Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.15958 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Teodoro J Oscanoa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Geriatric Department, Hospital Nacional Guillermo Almenara Irigoyen, ESSALUD, Lima, Peru. Hauptthemen laut MEDLINE: Warfarin, Anticoagulants. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Kaelin Award, Instituto de Evaluación e Investigación de Tecnologías de la Salud-IETSI.
Abstract (Originalsprache)
Aims
The aim of this study was to investigate the association between VKORC1 and CYP2C9 genes polymorphisms and the maintenance dose of warfarin in Peruvian patients.
Methods
An observational study was conducted on outpatients from the Hospital Grau ESSALUD in Lima, Peru. The participants were selected using nonprobabilistic convenience sampling. Inclusion criteria required patients to have been on anticoagulation therapy for >3 months, maintain stable doses of warfarin (consistent dose for at least 3 outpatient visits), and maintain an international normalized ratio within the therapeutic range of 2.5–3.5. DNA samples were obtained from peripheral blood for gene analysis.
Results
Seventy patients (mean age of 69.6 ± 13.4 years, 45.7% female) were included in the study. The average weekly warfarin dose was 31.6 ± 15.2 mg. The genotypic frequencies of VKORC1 were as follows: 7.1% (95% confidence interval, 2.4–15.9) for AA; 44.3% (32.4–56.7) for GA; and 48.6% (36.4–60.8) for GG. No deviation from the Hardy–Weinberg equilibrium was observed in the variants studied ( P = .56). The mean weekly warfarin doses for AA, GA and GG genotypes were 16.5 ± 2.9, 26.5 ± 9.5 and 37.9 ± 17.1 mg, respectively ( P < .001). The genotypic frequencies of CYP2C9 were as follows: 82.8% (72.0–90.8) for CC (*1/*1); 4.3% (1.0–12.0) for CT (*1/*2); and 12.9% (6.1–23.0) for TT (*2/*2). We did not find a significant association between the CYP2C9 gene polymorphism and the dose of warfarin.
Conclusions
The AA genotype of the VKORC1 gene was associated with a lower maintenance dose of warfarin in Peruvian patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Geriatric Department, Hospital Nacional Guillermo Almenara Irigoyen, ESSALUD, Lima, Peru.
- Facultad de Medicina Humana, Universidad de San Martín de Porres, Lima, Peru.
- Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Peru.
- Centro de Investigación de Genética y Biología Molecular, Universidad de San Martín de Porres, Facultad de Medicina Humana, Lima, Peru.
- Hematology Department, Hospital Emergencia Grau, ESSALUD, Lima, Peru.
- Discipline of Medical Gerontology, School of Medicine, Mercer's Institute for Successful Ageing, St James's Hospital, Dublin, Ireland.
ORCID-Profile: Teodoro J Oscanoa
Förderung
- Kaelin Award, Instituto de Evaluación e Investigación de Tecnologías de la Salud-IETSI
Zitieren
APA
Oscanoa, T. J., Guevara-Fujita, M. L., Fujita, R. M., Muñoz-Paredes, M. Y., Acosta, O., & Romero-Ortuño, R. (2024). Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15958
Vancouver
Oscanoa TJ, Guevara-Fujita ML, Fujita RM, Muñoz-Paredes MY, Acosta O, Romero-Ortuño R. Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.15958
BibTeX
@article{Oscanoa2024,
author = {Oscanoa, Teodoro J and Guevara-Fujita, María L and Fujita, Ricardo M and Muñoz-Paredes, Maria Y and Acosta, Oscar and Romero-Ortuño, Román},
title = {Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.15958}
}
EUVIMED